TORONTO and WINNIPEG, March 26 /CNW/ - Cangene Corporation today
announces that its HepaGam B(TM) (Hepatitis B Immune Globulin Intravenous
(Human)), has received orphan-drug exclusive approval from the United States
Food and Drug Administration ("FDA") for the prevention of hepatitis B
recurrence following liver transplantation in hepatitis B surface antigen
("HbsAG")-positive liver transplant patients. This approval gives HepaGam B
seven years of market exclusivity and could facilitate the recovery of certain
regulatory filing fees.